Diabetes patients find it difficult to obtain drugs that have become weight-loss drugs

Some diabetes patients are struggling to get their hands on drugs crucial to their health because they contain the same active ingredient as a sought-after weight-loss drug that is not yet sold in Israel, it was reported on Tuesday.

Ozempic, a drug used by diabetics to regulate blood sugar, contains semaglutide, which can be used for weight loss, but at a lower dose than Wegovy, an injectable obesity drug that can help its user lose 15 % of its body weight after one year. long-term treatment but will not be available in Israel until early 2023.

Thousands of potential Wegovy customers therefore used Ozempic as a substitute, causing supplies to run out and preventing some pharmacies from supplying the drug to diabetic patients, Channel 12 reported.

“Last week I was forced to stop 10 patients on Ozempic because they couldn’t get the medicine, and give them a different medicine which I think is less good,” said Dr. Ruthie Gorev told Channel 12.

Diabetes is a chronic disease in which the body does not produce enough insulin or cannot respond to it – a hormone created by the pancreas that allows blood sugar to enter cells to be used as energy. This leads to high blood sugar levels.

The Department of Health has so far refused to stop doctors from prescribing the diabetes drug to weight-loss patients, saying it would be an inappropriate intervention at doctors’ discretion.

Illustrative photo of overweight people hiking at the Wingate Institute in Israel. (Moshe Shai/Flash90)

Instead, the Department of Health sent a letter to pharmaceutical company Novo Nordisk asking it to work to ensure a “steady supply” of the drug. According to Channel 12, the company has already increased its Ozempic offer to Israel compared to other countries.

The Danish pharmaceutical multinational reportedly said it would “work transparently alongside the Ministry of Health” to ensure access to the drug for those who need it.

According to recent data from the World Health Organization published in 2022, 26.1% of adult Israelis suffer from obesity, including 25.9% of men and 26.2% of women.

It’s not (only) about you.

Supporting The Times of Israel is not a transaction for an online service, like subscribing to Netflix. The ToI Community is for people like you who care about a common good: to ensure that balanced and responsible coverage of Israel continues to be freely available to millions of people around the world.

Of course, we’ll remove all ads from your page and you’ll have access to great community-only content. But your support gives you something deeper than that: the pride of joining something that really matters.

Join the Times of Israel community Join our community Already a member? Log in to stop seeing this

You are a dedicated reader

That’s why we started The Times of Israel ten years ago – to provide discerning readers like you with must-read coverage of Israel and the Jewish world.

So now we have a request. Unlike other media, we don’t have a paywall in place. But since the journalism we do is expensive, we invite readers to whom The Times of Israel has become important to help support our work by joining The Times of Israel community.

For just $6 a month, you can help support our quality journalism while benefiting from The Times of Israel WITHOUT ADVERTISINGas well as access Exclusive Content only available to members of the Times of Israel community.

Thanks,
David Horovitz, founding editor of The Times of Israel

Join our community Join our community Already a member? Log in to stop seeing this

Leave a Comment